A citation-based method for searching scientific literature

Lynn E Sullivan, Brent A Moore, Patrick G O'Connor, Declan T Barry, Marek C Chawarski, Richard S Schottenfeld, David A Fiellin. Am J Addict 2010
Times Cited: 45







List of co-cited articles
212 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience.
Daniel P Alford, Colleen T LaBelle, Natalie Kretsch, Alexis Bergeron, Michael Winter, Michael Botticelli, Jeffrey H Samet. Arch Intern Med 2011
173
20

The effect of persistence of cocaine use on 12-month outcomes for the treatment of heroin dependence.
Anna Williamson, Shane Darke, Joanne Ross, Maree Teesson. Drug Alcohol Depend 2006
56
17

Understanding polydrug use: review of heroin and cocaine co-use.
Francesco Leri, Julie Bruneau, Jane Stewart. Addiction 2003
284
17

Buprenorphine retention in primary care.
Michael D Stein, Patricia Cioe, Peter D Friedmann. J Gen Intern Med 2005
126
17

Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence.
Lisa A Marsch, Mary Ann Chutuape Stephens, Timothy Mudric, Eric C Strain, George E Bigelow, Rolley E Johnson. Exp Clin Psychopharmacol 2005
54
15

Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study.
Michael Soyka, Christina Zingg, Gabriele Koller, Heinrich Kuefner. Int J Neuropsychopharmacol 2008
111
13

Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study.
Jessica A Dreifuss, Margaret L Griffin, Katherine Frost, Garrett M Fitzmaurice, Jennifer Sharpe Potter, David A Fiellin, Jeffrey Selzer, Mary Hatch-Maillette, Susan C Sonne, Roger D Weiss. Drug Alcohol Depend 2013
87
13

Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users.
Chinazo O Cunningham, Angela Giovanniello, Hillary V Kunins, Robert J Roose, Aaron D Fox, Nancy L Sohler. Am J Addict 2013
23
26

Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Yih-Ing Hser, Andrew J Saxon, David Huang, Al Hasson, Christie Thomas, Maureen Hillhouse, Petra Jacobs, Cheryl Teruya, Paul McLaughlin, Katharina Wiest,[...]. Addiction 2014
244
13

A trial of integrated buprenorphine/naloxone and HIV clinical care.
Lynn E Sullivan, Declan Barry, Brent A Moore, Marek C Chawarski, Jeanette M Tetrault, Michael V Pantalon, Patrick G O'Connor, Richard S Schottenfeld, David A Fiellin. Clin Infect Dis 2006
55
11

Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.
David A Fiellin, Linda Weiss, Michael Botsko, James E Egan, Frederick L Altice, Lauri B Bazerman, Amina Chaudhry, Chinazo O Cunningham, Marc N Gourevitch, Paula J Lum,[...]. J Acquir Immune Defic Syndr 2011
71
11

Alcohol and cocaine use and abuse among opioid addicts engaged in a methadone maintenance treatment program.
Icro Maremmani, Pier Paolo Pani, Anna Mellini, Matteo Pacini, Giada Marini, Mercedes Lovrecic, Giulio Perugi, Marc Shinderman. J Addict Dis 2007
58
11


Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
Paul J Fudala, T Peter Bridge, Susan Herbert, William O Williford, C Nora Chiang, Karen Jones, Joseph Collins, Dennis Raisch, Paul Casadonte, R Jeffrey Goldsmith,[...]. N Engl J Med 2003
372
11

Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors.
Lynn E Sullivan, Brent A Moore, Marek C Chawarski, Michael V Pantalon, Declan Barry, Patrick G O'Connor, Richard S Schottenfeld, David A Fiellin. J Subst Abuse Treat 2008
71
11

Predicting cocaine group treatment outcome in cocaine-abusing methadone patients.
Golfo K Tzilos, Gary L Rhodes, David M Ledgerwood, Mark K Greenwald. Exp Clin Psychopharmacol 2009
20
25

Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year.
Janet M Soeffing, L David Martin, Michael I Fingerhood, Donald R Jasinski, Darius A Rastegar. J Subst Abuse Treat 2009
104
11

Self-report among injecting drug users: a review.
S Darke. Drug Alcohol Depend 1998
852
11

Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients.
Brent A Moore, David A Fiellin, Declan T Barry, Lynn E Sullivan, Marek C Chawarski, Patrick G O'Connor, Richard S Schottenfeld. J Gen Intern Med 2007
119
11


Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years.
David A Fiellin, Brent A Moore, Lynn E Sullivan, William C Becker, Michael V Pantalon, Marek C Chawarski, Declan T Barry, Patrick G O'Connor, Richard S Schottenfeld. Am J Addict 2008
105
11

Factors associated with lapses to heroin use during methadone maintenance.
D A Wasserman, M G Weinstein, B E Havassy, S M Hall. Drug Alcohol Depend 1998
80
11

Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Richard P Mattick, Courtney Breen, Jo Kimber, Marina Davoli. Cochrane Database Syst Rev 2014
864
11

Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence.
Mehmet Sofuoglu, Gerardo Gonzalez, James Poling, Thomas R Kosten. Am J Drug Alcohol Abuse 2003
52
8

Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.
David A Fiellin, Michael V Pantalon, Marek C Chawarski, Brent A Moore, Lynn E Sullivan, Patrick G O'Connor, Richard S Schottenfeld. N Engl J Med 2006
240
8

State policy influence on the early diffusion of buprenorphine in community treatment programs.
Lori J Ducharme, Amanda J Abraham. Subst Abuse Treat Prev Policy 2008
70
8


Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up.
D S Metzger, G E Woody, A T McLellan, C P O'Brien, P Druley, H Navaline, D DePhilippis, P Stolley, E Abrutyn. J Acquir Immune Defic Syndr (1988) 1993
394
8

The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?
Lynn E Sullivan, Marek Chawarski, Patrick G O'Connor, Richard S Schottenfeld, David A Fiellin. Drug Alcohol Depend 2005
90
8

The Fifth Edition of the Addiction Severity Index.
A T McLellan, H Kushner, D Metzger, R Peters, I Smith, G Grissom, H Pettinati, M Argeriou. J Subst Abuse Treat 1992
8


Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
Roger D Weiss, Jennifer Sharpe Potter, David A Fiellin, Marilyn Byrne, Hilary S Connery, William Dickinson, John Gardin, Margaret L Griffin, Marc N Gourevitch, Deborah L Haller,[...]. Arch Gen Psychiatry 2011
339
8

Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-98.
Phillip O Coffin, Sandro Galea, Jennifer Ahern, Andrew C Leon, David Vlahov, Kenneth Tardiff. Addiction 2003
248
8

Prognostic factors in Buprenorphine- versus methadone-maintained patients.
R S Schottenfeld, J R Pakes, T R Kosten. J Nerv Ment Dis 1998
67
8

Factors associated with 12 months continuous heroin abstinence: findings from the Australian Treatment Outcome Study (ATOS).
Shane Darke, Joanne Ross, Maree Teesson, Robert Ali, Richard Cooke, Allison Ritter, Michael Lynskey. J Subst Abuse Treat 2005
61
8

Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians.
Cynthia L Arfken, Chris-Ellyn Johanson, Salvatore di Menza, Charles Roberts Schuster. J Subst Abuse Treat 2010
96
8

The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone.
Lynn E Sullivan, Michael Botsko, Chinazo O Cunningham, Patrick G O'Connor, David Hersh, Jennifer Mitty, Paula J Lum, Richard S Schottenfeld, David A Fiellin. J Acquir Immune Defic Syndr 2011
25
16

Patterns in admission delays to outpatient methadone treatment in the United States.
Jan Gryczynski, Robert P Schwartz, David S Salkever, Shannon Gwin Mitchell, Jerome H Jaffe. J Subst Abuse Treat 2011
53
8

Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence.
Ivan D Montoya, David A Gorelick, Kenzie L Preston, Jennifer R Schroeder, Annie Umbricht, Lawrence J Cheskin, W Robert Lange, Carlo Contoreggi, Rolley E Johnson, Paul J Fudala. Clin Pharmacol Ther 2004
97
8

A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial.
Johan Kakko, Leif Grönbladh, Kerstin Dybrandt Svanborg, Joachim von Wachenfeldt, Christian Rück, Bob Rawlings, Lars-Håkan Nilsson, Markus Heilig. Am J Psychiatry 2007
113
8

Does retention matter? Treatment duration and improvement in drug use.
Zhiwei Zhang, Peter D Friedmann, Dean R Gerstein. Addiction 2003
182
8

Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use.
D M Hartel, E E Schoenbaum, P A Selwyn, J Kline, K Davenny, R S Klein, G H Friedland. Am J Public Health 1995
136
8


Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence.
Richard S Schottenfeld, Marek C Chawarski, Juliana R Pakes, Michael V Pantalon, Kathleen M Carroll, Thomas R Kosten. Am J Psychiatry 2005
91
6

The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment.
Linda Weiss, James E Egan, Michael Botsko, Julie Netherland, David A Fiellin, Ruth Finkelstein. J Acquir Immune Defic Syndr 2011
38
7

Cocaine and crack use and HIV risk behaviors among high-risk methadone maintenance clients.
C E Grella, M D Anglin, S E Wugalter. Drug Alcohol Depend 1995
91
6

Effect of cocaine use on methadone pharmacokinetics in humans.
Elinore F McCance-Katz, Peter Jatlow, Petrie M Rainey. Am J Addict 2010
13
23


HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.
Frederick L Altice, R Douglas Bruce, Gregory M Lucas, Paula J Lum, P Todd Korthuis, Timothy P Flanigan, Chinazo O Cunningham, Lynn E Sullivan, Pamela Vergara-Rodriguez, David A Fiellin,[...]. J Acquir Immune Defic Syndr 2011
190
6

Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.
T V Parran, C A Adelman, B Merkin, M E Pagano, R Defranco, R A Ionescu, A G Mace. Drug Alcohol Depend 2010
86
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.